Hep C field is already too crowded.
Biota's Vapendavir, RSV and the anti-bacteria program should be the catalysts for big pharmaceuticals to look at.
- Forums
- ASX - By Stock
- BTA
- Ann: Relenza March Quarter Royalty
Ann: Relenza March Quarter Royalty , page-18
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
SPONSORED BY The Market Online